Clinical Trials Browser

Active not recruiting × OTHER × Melanoma × Clear all

NCT02713269 2026-04-17

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasms, Unknown Primary, Sarcoma, Spinal Cord Compression, Thyroid Neoplasms

NCT01590069 2026-04-16

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Phase 1 Active not recruiting

DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Sarcoma, Osteosarcoma

NCT05470283 2026-04-16

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Phase 1 Active not recruiting

Melanoma, Neoplasms

NCT01955460 2026-04-15

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Phase 1 Active not recruiting

Melanoma

NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT07531121 2026-04-15

ctDNA for Risk Stratification in Melanoma

Active not recruiting

Melanoma

NCT02656706 2026-04-13

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Phase 2 Active not recruiting

22 enrolled 10 charts

Melanoma

NCT05289193 2026-04-07

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Phase 2 Active not recruiting

Melanoma

NCT05703269 2026-04-06

HYPOGRYPHE

Phase NA Active not recruiting

BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Small Cell Lung Carcinoma

NCT05130177 2026-03-31

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase 2 Active not recruiting

Melanoma

NCT04074096 2026-03-25

BEPCOME-MB

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04930783 2026-03-25

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Phase 1 Active not recruiting

Melanoma

NCT06008977 2026-03-25

EX-BOOST

Phase NA Active not recruiting

Melanoma, Carcinoma, Merkel Cell

NCT00338377 2026-03-20

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma, Meningeal Neoplasms

NCT04899908 2026-03-19

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Phase 2 Active not recruiting

BreastCNSDermatologicGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT04478318 2026-03-10

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

Phase NA Active not recruiting

DermatologicLymphoidThoracic

Lung Neoplasms, Lymphoma, Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Active not recruiting

71 enrolled 9 charts

Melanoma

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

Melanoma

NCT00835133 2026-03-06

Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma

Active not recruiting

DermatologicGastrointestinal

Pancreatic carcinoma, familial, Melanoma, Neoplasms

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Phase 2 Active not recruiting

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT01644591 2026-03-05

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

Phase 2 Active not recruiting

DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Phase 2 Active not recruiting

14 enrolled 9 charts

Melanoma

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT04990726 2026-02-27

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Active not recruiting

Melanoma

NCT07428252 2026-02-25

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

Phase NA Active not recruiting

Melanoma

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Phase 1 Active not recruiting

Melanoma

NCT04971499 2026-02-20

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Phase 1/2 Active not recruiting

Melanoma

NCT05488483 2026-02-19

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

Active not recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1/2 Active not recruiting

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT05912244 2026-02-17

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Phase 2 Active not recruiting

Melanoma

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Phase 2 Active not recruiting

Melanoma

NCT05863052 2026-02-10

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Active not recruiting

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis

NCT04866680 2026-02-09

PERCIMEL

Phase NA Active not recruiting

Melanoma

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03420508 2026-02-05

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Phase 2 Active not recruiting

Melanoma

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Skin Neoplasms

NCT05418972 2026-02-05

Neo ReNi II

Phase 2 Active not recruiting

Melanoma

NCT04645680 2026-01-30

DIET

Phase 2 Active not recruiting

Uveal Melanoma, Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Phase 2 Active not recruiting

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT05121545 2026-01-29

ProGRID

Phase NA Active not recruiting

DermatologicSarcoma

Melanoma, Sarcoma

NCT07376317 2026-01-29

OTIMAS

Phase 2 Active not recruiting

Melanoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT03021460 2026-01-20

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Melanoma

NCT00508443 2026-01-15

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalLymphoidSarcomaThoracic

Urogenital Diseases, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasms, Sarcoma, Spinal Diseases, Spinal Neoplasms

NCT00582647 2026-01-15

Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Active not recruiting

DermatologicGastrointestinalSarcoma

Bile Duct Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT02724488 2026-01-08

SPECIAL

Active not recruiting

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma

NCT05034536 2026-01-08

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma